The fluoronietric iirocetluie for determining coproporphyrin requires collecting a 24-hi', urine specimen, from which a 5-mi. aliquot is used for the determination.
The coproporphyrin precursor is convei'ted to the fluorescent porphyrin by allowing the urine to stand for 24 hr., or by treating the urine with a dilute iodine solution.
The urine is buffered with sodium acetate buff ci', pH 4.8, and extracted with ethyl acetate.
The coproporphyrin is reextracted from ethyl acetate with 
Coproporphyrin Determination
1. Five milliliters of unfiltered urine is used containing 1.25 g. or less of coproporphyrin.
Where larger quantities of porphyrins are present, the urine should be diluted with distilled water.
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2. The nrine is placed in a 250-ml. separatory funnel and 5 ml. of acetate buffer, 10 ml. of water, and 100 ml. of ethyl acetate are added. If urine is fresh, 10 nil. of 0.005% iodine is added.
The funiiel is shaken for 1 miii. and the phases are allowed to separate.
The urine is discarded.
3. The ethyl acetate is washed with two 10-mi. portions of sodium acetate.
The A third cuvet, containing 1.5 N HC1, is measured to obtain the blank (B).
Calculation
The fluorescence of coproporphyrin in 1.5 N HC1 saturated with ethyl acetate is approximately 8% greater than that in pure 1.5 N HCI. A correction factor of 0.925 is therefore used. The working standard contains 0.05 g./ml. of coproporphyrin. Thus, the coproporphyrin in the original aliquot from the urine sample is, in micrograms:
Where a 5-mi. urine sample is used, the daily excretion, in micrograms, I X 0.231 X 24-hr. volume in ml.
in pathologic cases where a smaller urine sample is used, the daily excretion, in micrograms, is 
Rn -B X X Urine volume in ml.
These calculations assume a 25-ml. extraction volume from
Step 5.
If a larger extraction volume is used, appropriate correction must be made (4).
To effect the analysis by the random procedure, the coproporphyriim value obtained under Calculation 1 in the Talman procedure is substituted as follows:
Coproporphyrin
ml. (urine)
.
Creatinine (1 ml 
Results
This procedure proposed for coproporphyrin determination, based on the excretion of creatinine after initial determination of coproporphyrin, has proved to be functional. Table 1 gives the concentration of coproporphyrin in a 24-hr. urine and the value of randomly determined coproporphyrins in the same 24-hr. period.
The urines for this comparison were from a group of 9 healthy employees. A period of 5 consecutive days was set for collecting the urines, with a coproporphyrin and creatinine analysis performed on a random urine from each subject during each 8-hr. period.
As may be seen from According to Schwartz (2), the normal coproporphyrin excretion for males is 100-300 pg., and for females, 75-275 g.
The fluctuation in coproporphyrin excretion is not significant in determining coproporphyrin by the random procedure since excretion from normal subjects remain within the normal range. In the further investigation of this procedure, coproporphyrin random analysis was performed on urines from 100 employees and patients.
Employees were considered healthy. Some of the patients had dysfunctions which would be accompanied by an increase in coproporphyrin excretion. Table 2 gives some of the coproporphyrin values from this group.
First day. tSecond day. mal subjects, when substituted in the formula for calculation, gives values within the normal range, as shown in Fig. 1 . A value for the ratio of 1 or greater (as in Fig. 2 ) indicates values approaching the abnormal range for coproporphyrin. The ratio factor in the subject with leukemia shows aii abnormal excretion with the exception of one instance, shown in Figure 2 , when the coproporphyrin value for this patient fell within the normal range on the ninth day of the investigation. Coproporphyrin and creatinnie values for 12 consecutive days from random urines of a healthy subject and from a patient with leukemia are illustrated in Fig. 1 and 2 . The coproporphyrin-creatinine ratio in 1 ml. of urine from all nor-
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